Ocuphire Pharma (OCUP)
(Delayed Data from NSDQ)
$2.04 USD
+0.05 (2.51%)
Updated Jul 25, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OCUP 2.04 +0.05(2.51%)
Will OCUP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for OCUP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OCUP
The Beauty Health Company (SKIN) Reports Q1 Loss, Tops Revenue Estimates
Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?
OCUP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now
Merck (MRK) Gets EU Nod for Expanded Use in Gastric Cancer
FDA Expands Merck's (MRK) Welireg Label in Renal Cell Carcinoma
Other News for OCUP
Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July
These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
Ocuphire Pharma announces presentations on development of APX3330
Duos Technologies And 2 Other Stocks Under $3 Insiders Are Buying